


Typhoid vaccine over 81% effective in tackling disease in Nepal

December 4 2019



Salmonella Typhi. Image: Dr. Volker Brinkmann, MPI for Infection Biology

Caused by the bacterium Salmonella Typhi, typhoid is a major cause of fever in children in low- and middle-income countries and is responsible for nearly 11 million cases and more than 116,000 deaths a year worldwide.

In 2018, the World Health Organization (WHO) recommended the introduction of TCV for infants and children over six months of age in typhoid-endemic countries, and added it to its list of prequalified



vaccines.

Although TCV has been shown to protect against the disease in studies involving healthy volunteers in the UK, no efficacy studies in endemic populations had been completed.

Now, the Typhoid Vaccine Acceleration Consortium (TyVAC), which includes researchers from the University of Oxford, the University of Maryland School of Medicine, and PATH has completed a large field study in Nepal and published the interim analysis in the *New England Journal of Medicine*.

The study involved 20,000 children aged 9 months to

Citation: Typhoid vaccine over 81% effective in tackling disease in Nepal (2019, December 4) retrieved 26 April 2024 from <u>https://medicalxpress.com/news/2019-12-typhoid-vaccine-effective-tackling-disease.html</u>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.